HIV-단백질분해효소 억제제의 발견과 발전 (Korean Wikipedia)

Analysis of information sources in references of the Wikipedia article "HIV-단백질분해효소 억제제의 발견과 발전" in Korean language version.

refsWebsite

Global rank Korean rank

9doi.org

2^nd place

3^rd place

9nih.gov

4^th place

3archive.org

6^th place

18^th place

3semanticscholar.org

11^th place

310^th place

3web.archive.org

1^st place

2gsk.com

low place

1harvard.edu

18^th place

27^th place

1medscape.com

719^th place

424^th place

1uptodate.com

3,771^st place

3,916^th place

archive.org

Yanchunas Jr, J; Langley, D. R.; Tao, L; Rose, R. E.; Friborg, J; Colonno, R. J.; Doyle, M. L. (2005). “Molecular basis for increased susceptibility of isolates with atazanavir resistance-conferring substitution I50L to other protease inhibitors”. 《Antimicrobial Agents and Chemotherapy》 49 (9): 3825–32. doi:10.1128/AAC.49.9.3825-3832.2005. PMC 1195399. PMID 16127059.
Brunton, L.L.; Lazo, J.S.; Parker, K.L. (2006). 《Goodman and Gilmans's The Pharmacological Basis of Therapeutics》 11판. McGraw-Hill.
Brunton, L.L.; Lazo, J.S.; Parker, K.L. (2006). 《Goodman and Gilmans's The Pharmacological Basis of Therapeutics》 11판. McGraw-Hill.

doi.org

dx.doi.org

Cuccioloni, M; Mozzicafreddo, M; Bonfili, L; Cecarini, V; Eleuteri, A. M.; Angeletti, M (2009). “Natural occurring polyphenols as template for drug design. Focus on serine proteases”. 《Chemical Biology & Drug Design》 74 (1): 1–15. doi:10.1111/j.1747-0285.2009.00836.x. PMID 19519739.
Chen, X; Kempf, D. J.; Li, L; Sham, H. L.; Vasavanonda, S; Wideburg, N. E.; Saldivar, A; Marsh, K. C.; McDonald, E; Norbeck, D. W. (2003). “Synthesis and SAR studies of potent HIV protease inhibitors containing novel dimethylphenoxyl acetates as P2 ligands”. 《Bioorganic & Medicinal Chemistry Letters》 13 (21): 3657–60. doi:10.1016/j.bmcl.2003.08.043. PMID 14552751.
Adachi, M; Ohhara, T; Kurihara, K; Tamada, T; Honjo, E; Okazaki, N; Arai, S; Shoyama, Y; Kimura, K; Matsumura, H; Sugiyama, S; Adachi, H; Takano, K; Mori, Y; Hidaka, K; Kimura, T; Hayashi, Y; Kiso, Y; Kuroki, R (2009). “Structure of HIV-1 protease in complex with potent inhibitor KNI-272 determined by high-resolution X-ray and neutron crystallography”. 《Proceedings of the National Academy of Sciences》 106 (12): 4641–6. Bibcode:2009PNAS..106.4641A. doi:10.1073/pnas.0809400106. PMC 2660780. PMID 19273847.
Yanchunas Jr, J; Langley, D. R.; Tao, L; Rose, R. E.; Friborg, J; Colonno, R. J.; Doyle, M. L. (2005). “Molecular basis for increased susceptibility of isolates with atazanavir resistance-conferring substitution I50L to other protease inhibitors”. 《Antimicrobial Agents and Chemotherapy》 49 (9): 3825–32. doi:10.1128/AAC.49.9.3825-3832.2005. PMC 1195399. PMID 16127059.
Brower, E. T.; Bacha, U. M.; Kawasaki, Y; Freire, E (2008). “Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use”. 《Chemical Biology & Drug Design》 71 (4): 298–305. doi:10.1111/j.1747-0285.2008.00647.x. PMID 18312292. S2CID 8461472.
Kurup, Alka; Mekapati, Suresh; Garg, Rajni; Hansch, Corwin (2003). “HIV-1 Protease Inhibitors: A Comparative QSAR Analysis”. 《Current Medicinal Chemistry》 10 (17): 1679–88. doi:10.2174/0929867033457070. PMID 12871116.
Shi, Haibin; Liu, Kai; Leong, Wendy W.Y.; Yao, Shao Q. (2009). “Expedient solid-phase synthesis of both symmetric and asymmetric diol libraries targeting aspartic proteases”. 《Bioorganic & Medicinal Chemistry Letters》 19 (14): 3945–8. doi:10.1016/j.bmcl.2009.03.041. PMID 19328682.
Turk, Boris (2006). “Targeting proteases: successes, failures and future prospects”. 《Nature Reviews Drug Discovery》 5 (9): 785–99. doi:10.1038/nrd2092. PMID 16955069. S2CID 4156908.
Brower, E. T.; Bacha, U. M.; Kawasaki, Y; Freire, E (2008). “Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use”. 《Chemical Biology & Drug Design》 71 (4): 298–305. doi:10.1111/j.1747-0285.2008.00647.x. PMID 18312292. S2CID 8461472.

gsk.com

“Archived copy”. 2008년 12월 3일에 원본 문서에서 보존된 문서. 2008년 6월 11일에 확인함. GlaxoSmithKline discontinues clinical development of investigational protease inhibitor brecanavir (640385). Retrieved November 4th. 2009.
“Archived copy”. 2009년 8월 31일에 원본 문서에서 보존된 문서. 2009년 11월 5일에 확인함. GSK and Concert Pharmaceuticals form alliance to develop novel deuterium-modified drugs. Retrieved November 4th. 2009.

harvard.edu

adsabs.harvard.edu

Adachi, M; Ohhara, T; Kurihara, K; Tamada, T; Honjo, E; Okazaki, N; Arai, S; Shoyama, Y; Kimura, K; Matsumura, H; Sugiyama, S; Adachi, H; Takano, K; Mori, Y; Hidaka, K; Kimura, T; Hayashi, Y; Kiso, Y; Kuroki, R (2009). “Structure of HIV-1 protease in complex with potent inhibitor KNI-272 determined by high-resolution X-ray and neutron crystallography”. 《Proceedings of the National Academy of Sciences》 106 (12): 4641–6. Bibcode:2009PNAS..106.4641A. doi:10.1073/pnas.0809400106. PMC 2660780. PMID 19273847.

medscape.com

emedicine.medscape.com

HIV Disease - eMedicine

nih.gov

ncbi.nlm.nih.gov

Cuccioloni, M; Mozzicafreddo, M; Bonfili, L; Cecarini, V; Eleuteri, A. M.; Angeletti, M (2009). “Natural occurring polyphenols as template for drug design. Focus on serine proteases”. 《Chemical Biology & Drug Design》 74 (1): 1–15. doi:10.1111/j.1747-0285.2009.00836.x. PMID 19519739.
Chen, X; Kempf, D. J.; Li, L; Sham, H. L.; Vasavanonda, S; Wideburg, N. E.; Saldivar, A; Marsh, K. C.; McDonald, E; Norbeck, D. W. (2003). “Synthesis and SAR studies of potent HIV protease inhibitors containing novel dimethylphenoxyl acetates as P2 ligands”. 《Bioorganic & Medicinal Chemistry Letters》 13 (21): 3657–60. doi:10.1016/j.bmcl.2003.08.043. PMID 14552751.
Adachi, M; Ohhara, T; Kurihara, K; Tamada, T; Honjo, E; Okazaki, N; Arai, S; Shoyama, Y; Kimura, K; Matsumura, H; Sugiyama, S; Adachi, H; Takano, K; Mori, Y; Hidaka, K; Kimura, T; Hayashi, Y; Kiso, Y; Kuroki, R (2009). “Structure of HIV-1 protease in complex with potent inhibitor KNI-272 determined by high-resolution X-ray and neutron crystallography”. 《Proceedings of the National Academy of Sciences》 106 (12): 4641–6. Bibcode:2009PNAS..106.4641A. doi:10.1073/pnas.0809400106. PMC 2660780. PMID 19273847.
Yanchunas Jr, J; Langley, D. R.; Tao, L; Rose, R. E.; Friborg, J; Colonno, R. J.; Doyle, M. L. (2005). “Molecular basis for increased susceptibility of isolates with atazanavir resistance-conferring substitution I50L to other protease inhibitors”. 《Antimicrobial Agents and Chemotherapy》 49 (9): 3825–32. doi:10.1128/AAC.49.9.3825-3832.2005. PMC 1195399. PMID 16127059.
Brower, E. T.; Bacha, U. M.; Kawasaki, Y; Freire, E (2008). “Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use”. 《Chemical Biology & Drug Design》 71 (4): 298–305. doi:10.1111/j.1747-0285.2008.00647.x. PMID 18312292. S2CID 8461472.
Kurup, Alka; Mekapati, Suresh; Garg, Rajni; Hansch, Corwin (2003). “HIV-1 Protease Inhibitors: A Comparative QSAR Analysis”. 《Current Medicinal Chemistry》 10 (17): 1679–88. doi:10.2174/0929867033457070. PMID 12871116.
Shi, Haibin; Liu, Kai; Leong, Wendy W.Y.; Yao, Shao Q. (2009). “Expedient solid-phase synthesis of both symmetric and asymmetric diol libraries targeting aspartic proteases”. 《Bioorganic & Medicinal Chemistry Letters》 19 (14): 3945–8. doi:10.1016/j.bmcl.2009.03.041. PMID 19328682.
Turk, Boris (2006). “Targeting proteases: successes, failures and future prospects”. 《Nature Reviews Drug Discovery》 5 (9): 785–99. doi:10.1038/nrd2092. PMID 16955069. S2CID 4156908.
Brower, E. T.; Bacha, U. M.; Kawasaki, Y; Freire, E (2008). “Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use”. 《Chemical Biology & Drug Design》 71 (4): 298–305. doi:10.1111/j.1747-0285.2008.00647.x. PMID 18312292. S2CID 8461472.

semanticscholar.org

api.semanticscholar.org

Brower, E. T.; Bacha, U. M.; Kawasaki, Y; Freire, E (2008). “Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use”. 《Chemical Biology & Drug Design》 71 (4): 298–305. doi:10.1111/j.1747-0285.2008.00647.x. PMID 18312292. S2CID 8461472.
Turk, Boris (2006). “Targeting proteases: successes, failures and future prospects”. 《Nature Reviews Drug Discovery》 5 (9): 785–99. doi:10.1038/nrd2092. PMID 16955069. S2CID 4156908.
Brower, E. T.; Bacha, U. M.; Kawasaki, Y; Freire, E (2008). “Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use”. 《Chemical Biology & Drug Design》 71 (4): 298–305. doi:10.1111/j.1747-0285.2008.00647.x. PMID 18312292. S2CID 8461472.

uptodate.com

Graziani, Amy L (2014년 6월 17일). “HIV protease inhibitors”. UpToDate. 2021년 5월 20일에 원본 문서에서 보존된 문서. 2021년 5월 20일에 확인함.

web.archive.org

Graziani, Amy L (2014년 6월 17일). “HIV protease inhibitors”. UpToDate. 2021년 5월 20일에 원본 문서에서 보존된 문서. 2021년 5월 20일에 확인함.
“Archived copy”. 2008년 12월 3일에 원본 문서에서 보존된 문서. 2008년 6월 11일에 확인함. GlaxoSmithKline discontinues clinical development of investigational protease inhibitor brecanavir (640385). Retrieved November 4th. 2009.
“Archived copy”. 2009년 8월 31일에 원본 문서에서 보존된 문서. 2009년 11월 5일에 확인함. GSK and Concert Pharmaceuticals form alliance to develop novel deuterium-modified drugs. Retrieved November 4th. 2009.